Cargando…

Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)

Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general popula...

Descripción completa

Detalles Bibliográficos
Autores principales: Schernthaner, Guntram, Khunti, Kamlesh, Lotan, Chaim, Burnier, Michel, Drexel, Heinz, Prázný, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733371/
https://www.ncbi.nlm.nih.gov/pubmed/29276388
http://dx.doi.org/10.2147/TCRM.S144362
_version_ 1783286884407967744
author Schernthaner, Guntram
Khunti, Kamlesh
Lotan, Chaim
Burnier, Michel
Drexel, Heinz
Prázný, Martin
author_facet Schernthaner, Guntram
Khunti, Kamlesh
Lotan, Chaim
Burnier, Michel
Drexel, Heinz
Prázný, Martin
author_sort Schernthaner, Guntram
collection PubMed
description Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME(®) [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER(®)) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D.
format Online
Article
Text
id pubmed-5733371
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-57333712017-12-22 Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D) Schernthaner, Guntram Khunti, Kamlesh Lotan, Chaim Burnier, Michel Drexel, Heinz Prázný, Martin Ther Clin Risk Manag Perspectives Type 2 diabetes (T2D) imposes a substantial disease burden, predominantly from cardiovascular disease (CVD), which accounts for >50% of deaths in this population and leads to a 12-year reduction in the life expectancy of a 60-year-old male patient with T2D and CVD compared with the general population. The results from mandatory cardiovascular outcome trials (CVOTs) are therefore of great interest in the field. The Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes meeting program aims to bring together experts from several associated disciplines to provide fair and balanced resources for those involved in the management of patients with T2D. This publication represents the opinions of the faculty on the key learnings from the meeting held in Vienna in the spring of 2017. In particular, we detail how data from the EMPA-REG OUTCOME(®) [cardiovascular outcomes trial of empagliflozin] and Liraglutide Effect and Action in Diabetes: Evaluation of Cardiovascular Outcome Results (LEADER(®)) (liraglutide) CVOTs can be practically interpreted across clinical specialities. It is hoped that this translation of CVOT data will achieve a dual treatment paradigm for the management of both raised glucose levels and CV risk in patients with T2D. Dove Medical Press 2017-12-13 /pmc/articles/PMC5733371/ /pubmed/29276388 http://dx.doi.org/10.2147/TCRM.S144362 Text en © 2017 Schernthaner et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Perspectives
Schernthaner, Guntram
Khunti, Kamlesh
Lotan, Chaim
Burnier, Michel
Drexel, Heinz
Prázný, Martin
Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title_full Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title_fullStr Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title_full_unstemmed Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title_short Relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the Academy for Cardiovascular Risk, Outcomes and Safety Studies in Type 2 Diabetes (ACROSS T2D)
title_sort relevance of positive cardiovascular outcome trial results in clinical practice: perspectives from the academy for cardiovascular risk, outcomes and safety studies in type 2 diabetes (across t2d)
topic Perspectives
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5733371/
https://www.ncbi.nlm.nih.gov/pubmed/29276388
http://dx.doi.org/10.2147/TCRM.S144362
work_keys_str_mv AT schernthanerguntram relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d
AT khuntikamlesh relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d
AT lotanchaim relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d
AT burniermichel relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d
AT drexelheinz relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d
AT praznymartin relevanceofpositivecardiovascularoutcometrialresultsinclinicalpracticeperspectivesfromtheacademyforcardiovascularriskoutcomesandsafetystudiesintype2diabetesacrosst2d